Ciro Costagliola

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1666254/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effect of COVID-19-related lockdown on ophthalmic practice in Italy: A report from 39 institutional centers. European Journal of Ophthalmology, 2022, 32, 695-703.	0.7	35
2	Effects of topical low-dose preservative-free hydrocortisone on intraocular pressure in patients affected by ocular surface disease with and without glaucoma. Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260, 247-253.	1.0	3
3	Effectiveness of oral probiotics supplementation in the treatment of adult small chalazion. International Journal of Ophthalmology, 2022, 15, 40-44.	0.5	4
4	Topographic Outcomes in Keratoconus Surgery: Epi-on versus Epi-off Iontophoresis Corneal Collagen Cross-Linking. Journal of Clinical Medicine, 2022, 11, 1785.	1.0	5
5	Efficacy and Safety of Subthreshold Micropulse Yellow Laser for Persistent Diabetic Macular Edema After Vitrectomy: A Pilot Study. Frontiers in Pharmacology, 2022, 13, 832448.	1.6	6
6	Effect of a Fixed Combination of Curcumin, Artemisia, Bromelain, and Black Pepper Oral Administration on Optical Coherence Tomography Angiography Indices in Patients with Diabetic Macular Edema. Nutrients, 2022, 14, 1520.	1.7	6
7	Free Radical Properties, Source and Targets, Antioxidant Consumption and Health. Oxygen, 2022, 2, 48-78.	1.6	159
8	Dark halo, a new biomarker in macular neovascularization: comparison between OCT angiography and ICCA—a pilot prospective study. Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260, 3205-3211.	1.0	1
9	ls it time for a moratorium on the use of benzalkonium chloride in eyedrops?. British Journal of Clinical Pharmacology, 2022, 88, 3947-3949.	1.1	4
10	<i>In vitro</i> antimicrobial activity of ozonated oil in liposome eyedrop against multidrug-resistant bacteria. Open Medicine (Poland), 2022, 17, 1057-1063.	0.6	6
11	Ocular Tolerability of Bimatoprost 0.1 mg/mL Preservative-Free versus Bimatoprost 0.1 mg/mL with Benzalkonium Chloride or Bimatoprost 0.3 mg/mL Preservative-Free in Patients with Primary Open-Angle Glaucoma. Journal of Clinical Medicine, 2022, 11, 3518.	1.0	3
12	Anterior segment-optical coherence tomography and diabetic retinopathy: Could it be an early biomarker?. Photodiagnosis and Photodynamic Therapy, 2022, 39, 102995.	1.3	8
13	Effects of the first month of lockdown for COVID-19 in Italy: A preliminary analysis on the eyecare system from six centers. European Journal of Ophthalmology, 2021, 31, 2252-2258.	0.7	26
14	Pneumatic retinopexy preceded by drainage of subretinal fluid for the treatment of severe bullous retinal detachment. Acta Ophthalmologica, 2021, 99, e109-e116.	0.6	3
15	Intestinal microbiome: a new target for chalaziosis treatment in children?. European Journal of Pediatrics, 2021, 180, 1293-1298.	1.3	7
16	Ocular tropism of coronavirus (CoVs): a comparison of the interaction between the animal-to-human transmitted coronaviruses (SARS-CoV-1, SARS-CoV-2, MERS-CoV, CoV-229E, NL63, OC43, HKU1) and the eye. International Ophthalmology, 2021, 41, 349-362.	0.6	25
17	Fluorescein Angiography Findings in Eyes With Lamellar Macular Hole and Epiretinal Membrane Foveoschisis. , 2021, 62, 34.		7
18	Multimodal Imaging of Lamellar Macular Holes. Journal of Ophthalmology, 2021, 2021, 1-17.	0.6	4

#	Article	IF	CITATIONS
19	Influence of gut microbiota on eye diseases: an overview. Annals of Medicine, 2021, 53, 750-761.	1.5	38
20	Crosslinked Hyaluronic Acid with Liposomes and Crocin Confers Cytoprotection in an Experimental Model of Dry Eye. Molecules, 2021, 26, 849.	1.7	13
21	Compaction of very thin corneas from ultraviolet A riboflavin-vitamin E transepithelial cross-linking. Experimental Eye Research, 2021, 205, 108484.	1.2	1
22	Effectiveness of liposomal ozonized oil in reducing ocular microbial flora in patients undergoing cataract surgery. Journal of Cataract and Refractive Surgery, 2021, 47, 1548-1555.	0.7	7
23	Effects of Flavonoid Supplementation on Common Eye Disorders: A Systematic Review and Meta-Analysis of Clinical Trials. Frontiers in Nutrition, 2021, 8, 651441.	1.6	13
24	Unintentional Retinal Displacement in Eyes Treated for Rhegmatogenous Retinal Detachment Complicated by Proliferative Vitreoretinopathy with Pars Plana Vitrectomy and Silicone Oil. Journal of Ophthalmology, 2021, 2021, 1-8.	0.6	3
25	Topical Liposomal Ozonated Oil in Complicated Corneal Disease: A Report on Three Clinical Cases. International Medical Case Reports Journal, 2021, Volume 14, 327-332.	0.3	1
26	Probiotic Supplementation Improved Acute Anterior Uveitis of 3-Year Duration: A Case Report. American Journal of Case Reports, 2021, 22, e931321.	0.3	4
27	Targeting fibrosis in the failing heart with nanoparticles. Advanced Drug Delivery Reviews, 2021, 174, 461-481.	6.6	20
28	Cost-utility analysis of trabecular micro-bypass stents (TBS) in patients with mild-to-moderate open-angle Glaucoma in Italy. BMC Health Services Research, 2021, 21, 824.	0.9	12
29	Topo-Pachimetric Accelerated Epi-On Cross-Linking Compared to the Dresden Protocol Using Riboflavin with Vitamin E TPGS: Results of a 2-Year Randomized Study. Journal of Clinical Medicine, 2021, 10, 3799.	1.0	4
30	Comment on Real-Time In Vivo Assessment of Retinal Reattachment in Humans Using Swept-Source Optical Coherence Tomography. American Journal of Ophthalmology, 2021, , .	1.7	0
31	Lean approach to the management of patients undergoing intravitreal injections during COVID-19 pandemic. Therapeutic Advances in Ophthalmology, 2021, 13, 251584142110188.	0.8	3
32	AdipoRon negatively regulates proliferation and migration of ARPE-19 human retinal pigment epithelial cells. Peptides, 2021, 146, 170676.	1.2	3
33	How many aqueous humor outflow pathways are there?. Survey of Ophthalmology, 2020, 65, 144-170.	1.7	38
34	Effects of an antioxidant protective topical formulation on retinal tissue of UV-exposed rabbits. International Ophthalmology, 2020, 40, 925-933.	0.6	4
35	Intraocular pressure reduction with once-a-day application of a new prostaglandin eye drop: a pilot placebo-controlled study in 12 patients. International Ophthalmology, 2020, 40, 823-831.	0.6	0
36	FOVEA-SPARING VERSUS COMPLETE INTERNAL LIMITING MEMBRANE PEELING IN VITRECTOMY FOR THE TREATMENT OF MACULAR HOLES. Retina, 2020, 40, 1306-1314.	1.0	13

#	Article	IF	CITATIONS
37	PEELING OF THE INTERNAL LIMITING MEMBRANE WITH FOVEAL SPARING FOR TREATMENT OF DEGENERATIVE LAMELLAR MACULAR HOLE. Retina, 2020, 40, 1087-1093.	1.0	23
38	Topography and Pachymetry Guided, Rapid Epi-on Corneal Cross-Linking for Keratoconus: 7-year Study Results. Cornea, 2020, 39, 56-62.	0.9	9
39	>Minimally Invasive Surgery in Mild-to-Moderate Glaucoma Patients in Italy: Is It Time to Change?. Clinical Ophthalmology, 2020, Volume 14, 2639-2655.	0.9	7
40	Inverted ILM-flap techniques variants for macular hole surgery: randomized clinical trial to compare retinal sensitivity and fixation stability. Scientific Reports, 2020, 10, 15832.	1.6	16
41	A Novel Vitamin E TPGS-Based Formulation Enhances Chlorhexidine Bioavailability in Corneal Layers. Pharmaceutics, 2020, 12, 642.	2.0	13
42	Effects of Citicoline, Homotaurine, and Vitamin E on Contrast Sensitivity and Visual-Related Quality of Life in Patients with Primary Open-Angle Glaucoma: A Preliminary Study. Molecules, 2020, 25, 5614.	1.7	21
43	Aspirin in a diabetic retinopathy setting: Insights from NO BLIND study. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1806-1812.	1.1	2
44	The Importance of Telemedicine during COVID-19 Pandemic: A Focus on Diabetic Retinopathy. Journal of Diabetes Research, 2020, 2020, 1-8.	1.0	106
45	Antimycotic Activity of Ozonized Oil in Liposome Eye Drops against <i>Candida</i> spp Translational Vision Science and Technology, 2020, 9, 4.	1.1	18
46	Corneal UV Protective Effects of a Topical Antioxidant Formulation: A Pilot Study on In Vivo Rabbits. International Journal of Molecular Sciences, 2020, 21, 5426.	1.8	8
47	Effectiveness and Safety of Topical Chlorhexidine and Vitamin E TPGS in the Treatment of Acanthamoeba Keratitis: A Survey on 29 Cases. Journal of Clinical Medicine, 2020, 9, 3775.	1.0	3
48	High glucose concentration produces a short-term increase in pERK1/2 and p85 proteins, having a direct angiogenetic effect by an action similar to VEGF. Acta Diabetologica, 2020, 57, 947-958.	1.2	2
49	Reaction-diffusion model as framework for understanding the role of riboflavin in "eye defence― formulations. RSC Advances, 2020, 10, 14965-14971.	1.7	3
50	Do Ocular Fluids Represent a Transmission Route of SARS-CoV-2 Infection?. Frontiers in Medicine, 2020, 7, 620412.	1.2	7
51	Anti-inflammatory Effect of Curcumin, Homotaurine, and Vitamin D3 on Human Vitreous in Patients With Diabetic Retinopathy. Frontiers in Neurology, 2020, 11, 592274.	1.1	10
52	Comparative assessment of intraocular inflammation following standard or heavy silicone oil tamponade: a prospective study. Acta Ophthalmologica, 2019, 97, e97-e102.	0.6	27
53	The ocular surface after successful glaucoma filtration surgery: a clinical, in vivo confocal microscopy, and immune-cytology study. Scientific Reports, 2019, 9, 11299.	1.6	22
54	Relationship between albuminuric CKD and diabetic retinopathy in a real-world setting of type 2 diabetes: Findings from No blind study. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 923-930.	1.1	33

#	Article	IF	CITATIONS
55	Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an update. Expert Opinion on Drug Safety, 2019, 18, 803-815.	1.0	13
56	Foveal Abnormality associated with epiretinal Tissue of medium reflectivity and Increased blue-light fundus Autofluorescence Signal (FATIAS). Graefe's Archive for Clinical and Experimental Ophthalmology, 2019, 257, 2601-2612.	1.0	6
57	Morphological and Functional Evaluation of Oral Citicoline Therapy in Chronic Open-Angle Glaucoma Patients: A Pilot Study With a 2-Year Follow-Up. Frontiers in Pharmacology, 2019, 10, 1117.	1.6	17
58	Treatment of exudative ageâ€related macular degeneration with aflibercept combined with pranoprofen eye drops or nutraceutical support with omegaâ€3: A randomized trial. British Journal of Clinical Pharmacology, 2019, 85, 908-913.	1.1	13
59	A physicochemical study of ophthalmological vital dyes: From dimerization equilibrium in buffer solution to their liposomal dispersions. Dyes and Pigments, 2019, 162, 680-687.	2.0	3
60	Low-Tension Glaucoma: An Oxymoron in Ophthalmology. Preventing Chronic Disease, 2019, 16, E10.	1.7	2
61	Diabetic retinopathy, a vascular and inflammatory disease: Therapeutic implications. Diabetes and Metabolism, 2019, 45, 517-527.	1.4	124
62	High HDL cholesterol: A risk factor for diabetic retinopathy? Findings from NO BLIND study. Diabetes Research and Clinical Practice, 2019, 150, 236-244.	1.1	35
63	Human vitreous in proliferative diabetic retinopathy: Characterization and translational implications. Progress in Retinal and Eye Research, 2019, 72, 100756.	7.3	91
64	Impact of methylenetetrahydrofolate reductase C677T polymorphism on the efficacy of photodynamic therapy in patients with neovascular age-related macular degeneration. Scientific Reports, 2019, 9, 2614.	1.6	5
65	<p>Central Serous Chorioretinopathy: Pathogenesis and Management</p> . Clinical Ophthalmology, 2019, Volume 13, 2341-2352.	0.9	57
66	Ocular Refraction at Birth and Its Development During the First Year of Life in a Large Cohort of Babies in a Single Center in Northern Italy. Frontiers in Pediatrics, 2019, 7, 539.	0.9	12
67	EPIRETINAL MEMBRANE REMOVAL WITH FOVEAL-SPARING INTERNAL LIMITING MEMBRANE PEELING. Retina, 2019, 39, 2116-2124.	1.0	23
68	Melatonin: Implications for Ocular Disease and Therapeutic Potential. Current Pharmaceutical Design, 2019, 25, 4185-4191.	0.9	11
69	Visualization of Lamellar Hole-Associated Epiretinal Proliferation With Blue-Reflectance Imaging. Retina, 2018, 38, e34-e35.	1.0	3
70	Heavy and standard silicone oil: intraocular inflammation. International Ophthalmology, 2018, 38, 855-867.	0.6	33
71	Design of a novel heating device for infusion fluids in vitrectomy. Applied Thermal Engineering, 2018, 128, 625-636.	3.0	7
72	Phenytoin: its potential as neuroprotective and retinoprotective drug. British Journal of Clinical Pharmacology, 2018, 84, 195-196.	1.1	7

#	Article	IF	CITATIONS
73	ILM peeling in nontractional diabetic macular edema: review and metanalysis. International Ophthalmology, 2018, 38, 2709-2714.	0.6	18
74	Applicability of telemedicine in the screening of diabetic retinopathy (DR): The first multicentre study in Italy. The No Blind Study. Diabetes/Metabolism Research and Reviews, 2018, 35, e3113.	1.7	55
75	Intraretinal changes in idiopathic versus diabetic epiretinal membranes after macular peeling. PLoS ONE, 2018, 13, e0197065.	1.1	17
76	The retinoprotective role of phenytoin. Drug Design, Development and Therapy, 2018, Volume 12, 3485-3489.	2.0	9
77	Combination of ranibizumab and indomethacin for neovascular age-related macular degeneration: randomized controlled trial. Clinical Ophthalmology, 2018, Volume 12, 587-591.	0.9	4
78	Confocal microscopy of corneal nerve plexus as an early marker of eye involvement in patients with type 2 diabetes. Diabetes Research and Clinical Practice, 2018, 142, 393-400.	1.1	25
79	Epi-Off versus Epi-On Corneal Collagen Cross-Linking in Keratoconus Patients: A Comparative Study through 2-Year Follow-Up. Journal of Ophthalmology, 2018, 2018, 1-6.	0.6	30
80	The Relationship Between Blue-Fundus Autofluorescence and Optical Coherence Tomography in Eyes With Lamellar Macular Holes. , 2018, 59, 3079.		15
81	Lamellar macular holes in the eyes with pathological myopia. Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256, 1281-1290.	1.0	28
82	Effects of an Antioxidant Protective Topical Formulation on Eye Exposed to Ultraviolet-Irradiation: a Study in Rabbit Animal Model. Physiological Research, 2018, 67, 457-464.	0.4	10
83	On the use of uniaxial tests on the sclera to understand the difference between emmetropic and highly myopic eyes. Meccanica, 2017, 52, 603-612.	1.2	9
84	Comparison of half-dose photodynamic therapy and 689 nm laser treatment in eyes with chronic central serous chorioretinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 1141-1148.	1.0	27
85	Temperature Effect on Rheological Behavior of Silicone Oils. A Model for the Viscous Heating. Journal of Physical Chemistry B, 2017, 121, 7048-7054.	1.2	9
86	Controversies over the role of internal limiting membrane peeling during vitrectomy in macular hole surgery. Survey of Ophthalmology, 2017, 62, 58-69.	1.7	46
87	Dietary effect of dried bay leaves (<i>Laurus nobilis</i>) meal on some biochemical parameters and on plasma oxidative status in New Zealand white growing rabbit. Journal of Animal Physiology and Animal Nutrition, 2017, 101, e175-e184.	1.0	17
88	Reduced-fluence verteporfin photodynamic therapy plus ranibizumab for choroidal neovascularization in pathologic myopia. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 529-539.	1.0	11
89	Role of Lamellar Hole–Associated Epiretinal Proliferation in Lamellar Macular Holes. American Journal of Ophthalmology, 2017, 175, 16-29.	1.7	71
90	Cytoprotective Effects of Citicoline and Homotaurine against Glutamate and High Glucose Neurotoxicity in Primary Cultured Retinal Cells. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-7.	1.9	27

#	Article	IF	CITATIONS
91	Nanotechnology-Based Cardiac Targeting and Direct Cardiac Reprogramming: The Betrothed. Stem Cells International, 2017, 2017, 1-12.	1.2	22
92	Incidence and Factors Influencing Retinal Displacement in Eyes Treated for Rhegmatogenous Retinal Detachment With Vitrectomy and Gas or Silicone Oil. , 2017, 58, BIO191.		42
93	The Effect of Temperature Changes in Vitreoretinal Surgery. Translational Vision Science and Technology, 2016, 5, 4.	1.1	11
94	Resolvins and aliamides: lipid autacoids in ophthalmology – what promise do they hold?. Drug Design, Development and Therapy, 2016, Volume 10, 3133-3141.	2.0	17
95	<i>In Vivo</i> Near-Infrared Fluorescence Imaging of Aqueous Humor Outflow Structures. Journal of Ophthalmology, 2016, 2016, 1-6.	0.6	7
96	Arteriolar Diameters in Glaucomatous Eyes with Single-Hemifield Damage. Optometry and Vision Science, 2016, 93, 504-509.	0.6	5
97	Shallow Anterior Chamber After Trabeculectomy. Journal of Glaucoma, 2016, 25, 223-227.	0.8	3
98	REDUCTION OF VITREOUS PROSTAGLANDIN E2 LEVELS AFTER TOPICAL ADMINISTRATION OF INDOMETHACIN 0.5%, BROMFENAC 0.09%, AND NEPAFENAC 0.1%. Retina, 2016, 36, 1227-1231.	1.0	11
99	Comparison of Smartphone Ophthalmoscopy With Slit-Lamp Biomicroscopy for Grading Vertical Cup-to-Disc Ratio. Journal of Glaucoma, 2016, 25, e777-e781.	0.8	55
100	From the analysis of pharmacologic vitreolysis to the comprehension of ocriplasmin safety. Expert Opinion on Drug Safety, 2016, 15, 1267-1278.	1.0	6
101	Thermodynamic properties and photodegradation kinetics of indocyanine green in aqueous solution. Dyes and Pigments, 2016, 134, 342-347.	2.0	24
102	Effect of Autologous Serum Eye Drops in Patients with Sjögren Syndrome-related Dry Eye: Clinical and In Vivo Confocal Microscopy Evaluation of the Ocular Surface. In Vivo, 2016, 30, 931-938.	0.6	30
103	TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION WITH RANIBIZUMAB COMBINED WITH KETOROLAC EYEDROPS OR PHOTODYNAMIC THERAPY. Retina, 2015, 35, 1547-1554.	1.0	15
104	Restoration of Foveal Thickness and Architecture After Macula-Off Retinal Detachment Repair. Investigative Ophthalmology and Visual Science, 2015, 56, 1040-1050.	3.3	61
105	Effect of Factor XIII-A G185T Polymorphism on Visual Prognosis after Photodynamic Therapy for Neovascular Macular Degeneration. International Journal of Molecular Sciences, 2015, 16, 19796-19811.	1.8	5
106	A Novel Device to Exploit the Smartphone Camera for Fundus Photography. Journal of Ophthalmology, 2015, 2015, 1-5.	0.6	73
107	Palmitoylethanolamide, a Natural Retinoprotectant: Its Putative Relevance for the Treatment of Glaucoma and Diabetic Retinopathy. Journal of Ophthalmology, 2015, 2015, 1-9.	0.6	19
108	Diabetic Retinopathy: Vascular and Inflammatory Disease. Journal of Diabetes Research, 2015, 2015, 1-16.	1.0	287

#	Article	IF	CITATIONS
109	Current Trends about Inner Limiting Membrane Peeling in Surgery for Epiretinal Membranes. Journal of Ophthalmology, 2015, 2015, 1-13.	0.6	39
110	Comparison of Smartphone Ophthalmoscopy With Slit-Lamp Biomicroscopy for Grading Diabetic Retinopathy. American Journal of Ophthalmology, 2015, 159, 360-364.e1.	1.7	142
111	Development of ocular hypertension secondary to tamponade with light versus heavy silicone oil: A systematic review. Indian Journal of Ophthalmology, 2015, 63, 227.	0.5	17
112	Effect of intravitreal ranibizumab injections on aqueous humour concentrations of vascular endothelial growth factor and pigment epithelium-derived factor in patients with myopic choroidal neovascularisation. British Journal of Ophthalmology, 2015, 99, 1004-1008.	2.1	12
113	Efficacy and vitreous levels of topical NSAIDs. Expert Opinion on Drug Delivery, 2015, 12, 1767-1782.	2.4	18
114	Pharmacokinetic and Pharmacodynamic Properties of Anti-VEGF Drugs After Intravitreal Injection. Current Drug Metabolism, 2015, 16, 572-584.	0.7	41
115	Fractal dimension as a new tool to analyze optic nerve head vasculature in primary open angle glaucoma. In Vivo, 2015, 29, 273-9.	0.6	8
116	Latest Treatment Option and Technology Advancement in Corneal and Ocular Surface Disease. BioMed Research International, 2014, 2014, 1-2.	0.9	1
117	Anti-TNF therapy for juvenile idiopathic arthritis-related uveitis. Drug Design, Development and Therapy, 2014, 8, 341.	2.0	4
118	The p85 Regulatory Subunit of PI3K Mediates cAMP-PKA and Insulin Biological Effects on MCF-7 Cell Growth and Motility. Scientific World Journal, The, 2014, 2014, 1-11.	0.8	33
119	Diameters and Wall-to-Lumen Ratio of Retinal Arterioles in Patients with Retinal Vein Occlusion Before and After Treatment with Dexamethasone Intravitreal Implants. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 573-579.	0.6	6
120	Heavy Silicone Oil and Intraocular Inflammation. BioMed Research International, 2014, 2014, 1-16.	0.9	44
121	New Insight into Adiponectin Role in Obesity and Obesity-Related Diseases. BioMed Research International, 2014, 2014, 1-14.	0.9	425
122	Tamponade or Filling Effect: Changes of Forces in Myopic Eyes. BioMed Research International, 2014, 2014, 1-15.	0.9	14
123	Some Physicochemical Remarks on Spontaneous Emulsification of Vitreal Tamponades. BioMed Research International, 2014, 2014, 1-6.	0.9	5
124	Corneal Epithelial Wound Healing Promoted by Verbascoside-Based Liposomal Eyedrops. BioMed Research International, 2014, 2014, 1-8.	0.9	15
125	Using Canalography to Visualize the In Vivo Aqueous Humor Outflow Conventional Pathway in Humans. JAMA Ophthalmology, 2014, 132, 1281.	1.4	18
126	Ocular tissues and fluids oxidative stress in hares fed on verbascoside supplement. International Journal of Food Sciences and Nutrition, 2014, 65, 235-240.	1.3	15

#	Article	IF	CITATIONS
127	Neurotrophic Keratitis. Ophthalmologica, 2014, 231, 191-197.	1.0	87
128	Thermal analysis of milling products and its implications in self-ignition. Journal of Thermal Analysis and Calorimetry, 2014, 115, 1989-1998.	2.0	9
129	Inflammaging: should this term be suitable for age related macular degeneration too?. Inflammation Research, 2014, 63, 105-107.	1.6	25
130	Effect of Palmitoylethanolamide on Visual Field Damage Progression in Normal Tension Glaucoma Patients: Results of an Open-Label Six-Month Follow-Up. Journal of Medicinal Food, 2014, 17, 949-954.	0.8	19
131	In vitro and ex vivo retina angiogenesis assays. Angiogenesis, 2014, 17, 429-442.	3.7	76
132	Myopia onset and progression: can it be prevented?. International Ophthalmology, 2014, 34, 693-705.	0.6	22
133	Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview. Expert Opinion on Drug Safety, 2014, 13, 1-18.	1.0	44
134	Serum and intraocular concentrations of erythropoietin and vascular endothelial growth factor in patients with type 2 diabetes and proliferative retinopathy. Diabetes and Metabolism, 2014, 40, 445-451.	1.4	41
135	MACULAR HYPOTROPHY AFTER INTERNAL LIMITING MEMBRANE REMOVAL FOR DIABETIC MACULAR EDEMA. Retina, 2014, 34, 1182-1189.	1.0	29
136	Quality of vision in patients implanted with aspherical and spherical intraocular lens: Intraindividual comparison. Indian Journal of Ophthalmology, 2014, 62, 461.	0.5	4
137	Effect of intravitreal bevacizumab on serum, aqueous, and vitreous humor levels of erythropoietin in patients with proliferative diabetic retinopathy. Minerva Endocrinologica, 2014, 39, 305-11.	1.7	12
138	Lattice Corneal Dystrophy: a report of two cases in twin sisters due to 3 mutations (T1620C, C1416T,) Tj ETQq() 0	/Overlock 10
139	A novel exÂvivo murine retina angiogenesis (EMRA) assay. Experimental Eye Research, 2013, 112, 51-56.	1.2	30
140	Short-time prone posturing is well-tolerated and reduces the rate of unintentional retinal displacement in elderly patients operated on for retinal detachment. BMC Surgery, 2013, 13, S55.	0.6	24
141	Thermodynamics of Vitreoretinal Surgery. Current Eye Research, 2013, 38, 371-374.	0.7	16
142	Aqueous humor levels of vascular endothelial growth factor and adiponectin in patients with type 2 diabetes before and after intravitreal bevacizumab injection. Experimental Eye Research, 2013, 110, 50-54.	1.2	32
143	Inflammation and Macular Oedema after Pars Plana Vitrectomy. Mediators of Inflammation, 2013, 2013, 1-8.	1.4	43
144	TNF-Alpha Levels in Tears: A Novel Biomarker to Assess the Degree of Diabetic Retinopathy. Mediators of Inflammation, 2013, 2013, 1-6.	1.4	75

#	Article	IF	CITATIONS
145	Vitreous Mediators in Retinal Hypoxic Diseases. Mediators of Inflammation, 2013, 2013, 1-16.	1.4	35
146	Topical Nonsteroidal Anti-Inflammatory Drugs for Macular Edema. Mediators of Inflammation, 2013, 2013, 1-11.	1.4	45
147	Proliferative Vitreoretinopathy after Eye Injuries: An Overexpression of Growth Factors and Cytokines Leading to a Retinal Keloid. Mediators of Inflammation, 2013, 2013, 1-12.	1.4	107
148	Mechanism of Inflammation in Age-Related Macular Degeneration: An Up-to-Date on Genetic Landmarks. Mediators of Inflammation, 2013, 2013, 1-13.	1.4	52
149	In vivo confocal microscopy of meibomian glands in glaucoma. British Journal of Ophthalmology, 2013, 97, 343-349.	2.1	62
150	Influence of Retinal Vessel Printings on Metamorphopsia and Retinal Architectural Abnormalities in Eyes With Idiopathic Macular Epiretinal Membrane. , 2013, 54, 7803.		45
151	A randomised controlled trial of ranibizumab with and without ketorolac eyedrops for exudative age-related macular degeneration. British Journal of Ophthalmology, 2013, 97, 1273-1276.	2.1	16
152	Corneal oedema and its medical treatment. Australasian journal of optometry, The, 2013, 96, 529-535.	0.6	54
153	Effects of Verbascoside-Based Diet on Blood and Plasma Constituents of Rabbits. Journal of the American College of Nutrition, 2013, 32, 391-398.	1.1	7
154	Central Retinal Vein Occlusion Treated with Ozurdex: A Case Report and Review of Literature. Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 84-87.	0.6	2
155	Intravitreal Infliximab for Choroidal Neovascularization in Patients Refractory to Conventional Treatments. International Journal of Immunopathology and Pharmacology, 2013, 26, 765-768.	1.0	11
156	INTRAVITREAL PEGAPTANIB SODIUM (MACUGEN) FOR TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION. Retina, 2013, 33, 397-402.	1.0	21
157	Adult-Onset Cyclic Esotropia. Optometry and Vision Science, 2013, 90, e95-e98.	0.6	10
158	Recurrent Central Serous Chorioretinopathy after Peripheral Retinal Laser Photocoagulation: A Case Report. European Journal of Ophthalmology, 2013, 23, 258-261.	0.7	2
159	Aflibercept in wet AMD: specific role and optimal use. Drug Design, Development and Therapy, 2013, 7, 711.	2.0	108
160	Vitreous Analysis in the Management of Uveitis. Mediators of Inflammation, 2012, 2012, 1-7.	1.4	15
161	Mechanism of Inflammation in Age-Related Macular Degeneration. Mediators of Inflammation, 2012, 2012, 1-16.	1.4	102
162	Vitreo-papillary adhesion as a prognostic factor in pseudo- and lamellar macular holes. Eye, 2012, 26, 810-815.	1.1	18

#	Article	IF	CITATIONS
163	Relationship between media-to-lumen ratio of subcutaneous small arteries and wall-to-lumen ratio of retinal arterioles evaluated noninvasively by scanning laser Doppler flowmetry. Journal of Hypertension, 2012, 30, 1169-1175.	0.3	85
164	Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration. Expert Opinion on Biological Therapy, 2012, 12, 1299-1313.	1.4	48
165	Intravitreal bevacizumab versus low-fluence photodynamic therapy for treatment of chronic central serous chorioretinopathy. Japanese Journal of Ophthalmology, 2012, 56, 608-612.	0.9	48
166	Aqueous Humor Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Bevacizumab in Type 3 Versus Type 1 and 2 Neovascularization. A Prospective, Case-Control Study. American Journal of Ophthalmology, 2012, 153, 155-161.e2.	1.7	41
167	Pseudo-Foster Kennedy syndrome in a young woman with meningioma infiltrating the superior sagittal sinus. Clinical Neurology and Neurosurgery, 2012, 114, 272-274.	0.6	6
168	Defining reference values of trace elements in the tear film: Diagnostic methods and possible applications. Ecotoxicology and Environmental Safety, 2012, 80, 190-194.	2.9	17
169	Intravitreal pegaptanib sodium (Macugen®) for treatment of diabetic macular oedema: a morphologic and functional study. British Journal of Clinical Pharmacology, 2012, 74, 940-946.	1.1	20
170	Longitudinal Study of Macular Folds by Spectral-domain Optical Coherence Tomography. American Journal of Ophthalmology, 2012, 154, 757-758.	1.7	4
171	Conjunctival findings in hyperbaric and lowâ€ŧension glaucoma: an <i>in vivo</i> confocal microscopy study. Acta Ophthalmologica, 2012, 90, e132-7.	0.6	24
172	Histological findings of failed gold micro shunts in primary open-angle glaucoma. Graefe's Archive for Clinical and Experimental Ophthalmology, 2012, 250, 143-149.	1.0	46
173	Genetic Predictors of Response to Photodynamic Therapy. Molecular Diagnosis and Therapy, 2011, 15, 195-210.	1.6	9
174	Outer Retinal Layers. Ophthalmology, 2011, 118, 1006-1006.e2.	2.5	4
175	Floppy Iris Risk Factors. Ophthalmology, 2011, 118, 2094-2095.	2.5	Ο
176	Trisomy 1q42-qter Associated with Monosomy 6q27-qter: A Case Report. European Journal of Ophthalmology, 2011, 21, 315-319.	0.7	2
177	Correspondence. Retina, 2011, 31, 428-429.	1.0	3
178	Retinal Angiomatosis and Cystoid Macular Oedema in Cogan's Syndrome. Optometry and Vision Science, 2011, 88, E1262-E1266.	0.6	4
179	Editorial [Hot Topic: Therapeutic Approaches for Vision Loss due to Choroidal Neovascularizations in Age Related Macular Degeneration (Guest Editor: Ciro Costagliola)]. Current Drug Targets, 2011, 12, 133-137.	1.0	0
180	Age Related Macular Degeneration and Visual Disability. Current Drug Targets, 2011, 12, 221-233.	1.0	33

#	Article	IF	CITATIONS
181	TWENTY-THREE–GAUGE PARS PLANA VITRECTOMY, DENSIRON-68, AND 360° ENDOLASER VERSUS COMBINE 20-GAUGE PARS PLANA VITRECTOMY, SCLERAL BUCKLE, AND SF6 FOR PSEUDOPHAKIC RETINAL DETACHMENT WITH INFERIOR RETINAL BREAKS. Retina, 2011, 31, 686-691.	D 1.0	31
182	Clinical and Rehabilitative Management of Retinitis Pigmentosa:Up-to-Date. Current Genomics, 2011, 12, 250-259.	0.7	37
183	Acute juvenile cataract in newly diagnosed type 1 diabetic patients: a description of six cases. Pediatric Diabetes, 2011, 12, 642-648.	1.2	14
184	Predicting the risk of diabetic retinopathy in type 2 diabetic patients. Journal of Diabetes and Its Complications, 2011, 25, 292-297.	1.2	58
185	Good Epidemiologic Practice in Retinitis Pigmentosa: From Phenotyping to Biobanking. Current Genomics, 2011, 12, 260-266.	0.7	107
186	Systemic Adverse Drug Reactions Secondary to Anti-VEGF Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration. Current Vascular Pharmacology, 2011, 9, 629-646.	0.8	39
187	Role of Higher Dietary Carbohydrate Intake in Cataract Development. , 2011, 52, 3593.		7
188	Ocular manifestations in hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber disease): A case-series. Ophthalmic Genetics, 2011, 32, 12-17.	0.5	15
189	Pharmacogenetic Aspects in Therapeutic Management of Subfoveal Choroidal Neovascularisation: Role of Factor XIII-A 185 T-Allele. Current Drug Targets, 2011, 12, 138-148.	1.0	12
190	Enhanced Depth Imaging Spectral-Domain Optical Coherence Tomography. Retina, 2010, 30, 378-379.	1.0	15
191	Sutureless Human Sclera Donor Patch Graft for Ahmed Glaucoma Valve. European Journal of Ophthalmology, 2010, 20, 546-551.	0.7	30
192	Intraocular pressure changes following the use of silicone oil or Densiron® 68 as endotamponade in pars plana vitrectomy. Clinical Ophthalmology, 2010, 4, 1391.	0.9	18
193	Combined photodynamic therapy and intravitreal bevacizumab for idiopathic polypoidal choroidal vasculopathy: one-year follow-up. Clinical Ophthalmology, 2010, 4, 1237.	0.9	12
194	Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. British Journal of Ophthalmology, 2010, 94, 180-184.	2.1	33
195	Thrombophilia in the Occurrence of Retinal Vascular Infarction After Photodynamic Therapy With Verteporfin Using the Standard Protocol. JAMA Ophthalmology, 2010, 128, 1632.	2.6	2
196	Foveal Hypoautofluorescence: Does It Correlate to Visual Acuity in White Dot Syndromes?. JAMA Ophthalmology, 2010, 128, 1628.	2.6	1
197	Inflammatory Mediators and Angiogenic Factors in Choroidal Neovascularization: Pathogenetic Interactions and Therapeutic Implications. Mediators of Inflammation, 2010, 2010, 1-14.	1.4	170
198	Impact of Coagulation-Balance Gene Predictors on Efficacy of Photodynamic Therapy for Choroidal Neovascularization in Pathologic Myopia. Ophthalmology, 2010, 117, 517-523.	2.5	12

#	Article	IF	CITATIONS
199	Inferior Pseudophakic Retinal Detachment. Ophthalmology, 2010, 117, 2233.e3-2233.e4.	2.5	1
200	Epiretinal membrane in a 12-year-old immunocompetent girl with cytomegalovirus infection. European Journal of Ophthalmology, 2009, 19, 1098-1101.	0.7	4
201	Endophthalmitis. Anti-Infective Agents in Medicinal Chemistry, 2009, 8, 151-168.	0.6	0
202	Predictive role of C677T <i>MTHFR</i> polymorphism in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration. Pharmacogenomics, 2009, 10, 81-95.	0.6	25
203	Changes in neovascular choroidal morphology after intravitreal bevacizumab injection: prospective trial on 156 eyes throughout 12-month follow-up. Graefe's Archive for Clinical and Experimental Ophthalmology, 2009, 247, 1031-1037.	1.0	13
204	Pharmacotherapy of intraocular pressure: part I. Parasympathomimetic, sympathomimetic and sympatholytics. Expert Opinion on Pharmacotherapy, 2009, 10, 2663-2677.	0.9	72
205	Pharmacotherapy of intraocular pressure – part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opinion on Pharmacotherapy, 2009, 10, 2859-2870.	0.9	47
206	Multiple Strokes in a Newborn. Ophthalmology, 2009, 116, 812-813.e3.	2.5	3
207	INTRAVITREAL BEVACIZUMAB FOR TREATMENT-NAÃVE PATIENTS WITH SUBFOVEAL OCCULT CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION. Retina, 2009, 29, 1227-1234.	1.0	14
208	Predictive Role of Gene Polymorphisms Affecting Thrombin-Generation Pathway in Variable Efficacy of Photodynamic Therapy for Neovascular Age-Related Macular Degeneration. Recent Patents on DNA & Gene Sequences, 2009, 3, 114-122.	0.7	10
209	Circadian changes of intraocular pressure and ocular perfusion pressure after timolol or latanoprost in Caucasians with normal-tension glaucoma. Graefe's Archive for Clinical and Experimental Ophthalmology, 2008, 246, 389-396.	1.0	35
210	Retinal Phototoxicity Induced by Hydrochlorothiazide After Exposure to a UV Tanning Device. Photochemistry and Photobiology, 2008, 84, 1294-1297.	1.3	20
211	Intravitreal bevacizumab (Avastin®) injection for neovascular glaucoma: a survey on 23 cases throughout twelve-month follow-up. British Journal of Clinical Pharmacology, 2008, 66, 667-73.	1.1	42
212	Topical and Oral Ketorolac Administration Increases the Intraocular Pressure-Lowering Effect of Latanoprost. Current Eye Research, 2008, 33, 477-482.	0.7	10
213	Coagulation Gene Predictors of Photodynamic Therapy for Occult Choroidal Neovascularization in Age-Related Macular Degeneration. , 2008, 49, 3100.		38
214	12-MONTH RETROSPECTIVE STUDY AND REVIEW OF PHOTODYNAMIC THERAPY WITH VERTEPORFIN FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION. Retina, 2008, 29, 289-297.	1.0	16
215	Verteporfin Photodynamic Therapy for Subfoveal Choroidal Neovascularization in Pathologic Myopia: A 12-Month Retrospective Review. European Journal of Ophthalmology, 2008, 18, 955-959.	0.7	7
216	Selective Serotonin Reuptake Inhibitors: A Review of its Effects on Intraocular Pressure. Current Neuropharmacology, 2008, 6, 293-310.	1.4	62

#	Article	IF	CITATIONS
217	Intravitreal Bevacizumab for Choroidal Neovascularization Secondary to Angioid Streaks. JAMA Ophthalmology, 2007, 125, 1422.	2.6	43
218	Predictive role of coagulation-balance gene polymorphisms in the efficacy of photodynamic therapy with verteporfin for classic choroidal neovascularization secondary to age-related macular degeneration. Pharmacogenetics and Genomics, 2007, 17, 1039-1046.	0.7	38
219	Intravitreal Bevacizumab for the Treatment of Retinal Angiomatous Proliferation. American Journal of Ophthalmology, 2007, 144, 449-451.	1.7	42
220	Bilateral isolated acute cataracts in three newly diagnosed insulin dependent diabetes mellitus young patients. Diabetes Research and Clinical Practice, 2007, 76, 313-315.	1.1	11
221	Increased Retinal Blood Flow in Patients with Active Graves' Ophthalmopathy. Current Eye Research, 2007, 32, 985-990.	0.7	27
222	Total Aniridia After Nonperforating Trauma of a Pseudophakic Eye. Journal of Ultrasound in Medicine, 2007, 26, 1795-1797.	0.8	9
223	Effect of 2% dorzolamide on retinal blood flow: a study on juvenile primary open-angle glaucoma patients already receiving 0.5% timolol. British Journal of Clinical Pharmacology, 2007, 63, 376-379.	1.1	23
224	Nimesulide Oral Administration Increases the Intraocular pressure-lowering Effect of Latanoprost in Patients With Primary Open-angle Glaucoma. American Journal of Ophthalmology, 2006, 141, 379-381.	1.7	13
225	Vision Loss after PDT. Ophthalmology, 2006, 113, 157.e1-157.e4.	2.5	7
226	Possible ocular involvement in pulmonary alveolar proteinosis. European Respiratory Journal, 2006, 28, 456-456.	3.1	0
227	Endogenous Aspergillus versicolor Endophthalmitis in an Immuno-competent HIV-positive Patient. Mycopathologia, 2005, 160, 259-261.	1.3	24
228	The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients. Experimental Eye Research, 2005, 81, 610-615.	1.2	26
229	Clear Cell Renal Cell Carcinoma Associated with Bilateral Atypical Acute Posterior Multifocal Placoid Pigment Epitheliopathy. Oncology, 2004, 66, 502-509.	0.9	16
230	Macular coloboma in siblings affected by different phenotypes of retinitis pigmentosa. Eye, 2004, 18, 421-428.	1.1	7
231	Low-protein diet and progression of retinal degeneration in gyrate atrophy of the choroid and retina: A twenty-six-year follow-up. Journal of Inherited Metabolic Disease, 2004, 27, 187-196.	1.7	28
232	SSRIs and Intraocular Pressure Modifications. CNS Drugs, 2004, 18, 475-484.	2.7	69
233	Prevalence of factor XIII Val34Leu polymorphism in patients affected by spontaneous subconjunctival hemorrhage. American Journal of Ophthalmology, 2004, 138, 481-484.	1.7	14
234	Quantitative evaluation of the retinal venous tortuosity in chronic anaemic patients affected by β-thalassaemia major. Eye, 2003, 17, 324-329.	1.1	25

#	Article	IF	CITATIONS
235	Congenital adrenal hyperplasia due to 21-hydroxylase deficiency associated with bilateral keratoconus. American Journal of Ophthalmology, 2003, 135, 557-559.	1.7	7
236	Assessing the cost-effectiveness of switching from a β-blocker to latanoprost in the treatment of ocular hypertension. Expert Opinion on Pharmacotherapy, 2003, 4, 1775-1788.	0.9	16
237	Bilateral Neuroretinitis in a 6-Year-Old Boy With Acquired Toxoplasmosis. JAMA Ophthalmology, 2003, 121, 1493.	2.6	13
238	Ocular Perfusion Pressure and Visual Field Indice Modifications Induced by α-Agonist Compound (Clonidine 0.125%, Apraclonidine 1.0% and Brimonidine 0.2%) Topical Administration. Ophthalmologica, 2003, 217, 39-44.	1.0	20
239	Mesectodermal leiomyoma exclusively involving the posterior choroid. American Journal of Ophthalmology, 2002, 134, 451-454.	1.7	22
240	Recurrent episodes of spontaneous subconjunctival hemorrhage in patients with factor XIII Val34Leu mutation. American Journal of Ophthalmology, 2002, 134, 927-929.	1.7	13
241	Bilateral Central Serous Chorioretinopathy in a Patient Treated with Systemic Cortico-Steroids for Non-Hodgkin Lymphoma. European Journal of Ophthalmology, 2002, 12, 123-126.	0.7	12
242	Effects of acute topical administration of clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2% on visual field parameters and ocular perfusion pressure in patients with primary open-angle glaucoma. Acta Ophthalmologica, 2002, 80, 29-30.	0.4	6
243	Reproducibility of retinal thickness measurements with retinal thickness analyser in healthy and glaucomatous subjects. Acta Ophthalmologica, 2002, 80, 43-44.	0.4	3
244	Effect of 0.005% latanoprost once daily on intraocular pressure in glaucomatous patients not adequately controlled by beta-blockers twice daily: a 3-year follow-up. Graefe's Archive for Clinical and Experimental Ophthalmology, 2002, 240, 379-386.	1.0	34
245	The heterozygous 20210 G/A genotype prevalence in patients affected by central and branch retinal vein occlusion: a pilot study. Graefe's Archive for Clinical and Experimental Ophthalmology, 2001, 239, 251-256.	1.0	15
246	Perfusion of the optic nerve head and visual field damage in glaucomatous patients. , 2001, 239, 549-555.		28
247	Ocular surface changes induced by topical application of latanoprost and timolol: a short-term study in glaucomatous patients with and without allergic conjunctivitis. , 2001, 239, 809-814.		48
248	Bilateral circumscribed haemangioma of the choroid not associated with systemic vascular syndrome. British Journal of Ophthalmology, 2001, 85, 1260-1260.	2.1	9
249	Pattern Dystrophy of the Retinal Pigment Epithelium in Crohn's Disease. Ophthalmologica, 2000, 214, 441-446.	1.0	4
250	Effect of Fluoxetine on Intraocular Pressure in the Rabbit. Experimental Eye Research, 2000, 70, 551-555.	1.2	15
251	Effect of Oral Losartan Potassium Administration on Intraocular Pressure in Normotensive and Glaucomatous Human Subjects. Experimental Eye Research, 2000, 71, 167-171.	1.2	62
252	Extraocular Muscle Antibodies Positivity as the Only Serum Marker of Euthyroid Graves' Ophthalmopathy following Subacute Thyroiditis: Case Report. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 950-952.	1.8	4

#	Article	IF	CITATIONS
253	In vitro Viability of External Eye Microbial Flora in Hydroxy-Propyl-Methylcellulose. Ophthalmologica, 1999, 213, 265-268.	1.0	4
254	Axial Length Increase in Lid-Sutured Rabbits. Survey of Ophthalmology, 1999, 44, S103-S108.	1.7	14
255	Losartan Potassium Oral Administration Decreased Intraocular Pressure in Humans. Clinical Drug Investigation, 1999, 17, 329-332.	1.1	6
256	Lipoid Proteinosis (Urbach-Wiethe Disease). Ophthalmologica, 1999, 213, 392-396.	1.0	29
257	In vitro Staphylococcus epidermidis Growth in Some Viscoelastic Substances Containing Sodium Hyaluronate. Ophthalmologica, 1998, 212, 184-187.	1.0	3
258	Polycyclic Aromatic Hydrocarbons in Bovine Lens. Ophthalmic Research, 1997, 29, 172-176.	1.0	4
259	The ability of bacteria to use Na-hyaluronate as a nutrient. American Journal of Ophthalmology, 1997, 123, 868.	1.7	0
260	Photorefractive Keratectomy and Cataract. Survey of Ophthalmology, 1997, 42, S133-S140.	1.7	6
261	Ocular hypotensive effect of topical ketanserin in timolol users. Graefe's Archive for Clinical and Experimental Ophthalmology, 1997, 235, 130-135.	1.0	5
262	Ocular hypotensive effect of ketanserin in patients with primary open angle glaucoma. Acta Ophthalmologica, 1997, 75, 24-25.	0.4	5
263	The use of a standardized exercise as a provocative test in pigmentary dispersion syndrome. Acta Ophthalmologica, 1997, 75, 26-27.	0.4	1
264	Author??s Reply. Journal of Glaucoma, 1996, 5, 298.	0.8	0
265	Effect of Dapiprazole, an Alpha-Adrenergic Blocking Agent, on Aqueous Humor Dynamics in Pigmentary Glaucoma. Ophthalmic Research, 1996, 28, 312-318.	1.0	9
266	Fluoxetine oral administration increases intraocular pressure. British Journal of Ophthalmology, 1996, 80, 678-678.	2.1	22
267	Arf 193nm excimer laser corneal surgery and photo-oxidative stress in aqueous humor and lens of rabbit: one-month follow-up. Current Eye Research, 1996, 15, 355-361.	0.7	12
268	The ability of bacteria to use Naâ€hyaluronate as a nutrient. Acta Ophthalmologica, 1996, 74, 566-568.	0.4	12
269	Effect of Oral Captopril (SQ 14225) on Intraocular Pressure in Man. European Journal of Ophthalmology, 1995, 5, 19-25.	0.7	57
270	Effect of oral captopril (SQ 14225) on intraocular pressure in man. European Journal of Ophthalmology, 1995, 5, 19-25.	0.7	14

#	Article	IF	CITATIONS
271	ArF 193 nm Excimer Laser Corneal Surgery as a Possible Risk Factor in Cataractogenesis. Experimental Eye Research, 1994, 58, 453-457.	1.2	29
272	Effect of topical ketanserin administration on intraocular pressure British Journal of Ophthalmology, 1993, 77, 344-348.	2.1	34
273	Anemia and Chronic Renal Failure: A Therapeutical Approach by Reduced Glutathione Parenteral Administration. Nephron, 1992, 61, 404-408.	0.9	16
274	Isolated optic nerve involvement in chronic myeloid leukemia. Leukemia Research, 1992, 16, 411-413.	0.4	12
275	Retinal Hypoxia and Anemia in Chronic Renal Failure: Effect of Erythropoietin. , 1992, , 189-192.		0
276	Hyperprolactinemia and lens opacities. Annals of Ophthalmology, 1992, 24, 418-9.	0.0	0
277	Effect of oral ketanserin administration on intraocular pressure in glaucomatous patients. Experimental Eye Research, 1991, 52, 507-510.	1.2	18
278	Moraxella Lacunata Endophthalmitis after Intraocular Lens Implantation. European Journal of Implant and Refractive Surgery, 1991, 3, 152-155.	0.4	2
279	Ocular Findings in X-Linked Ichthyosis: A Survey on 38 Cases. Ophthalmologica, 1991, 202, 152-155.	1.0	40
280	The Takagi Automatic Tangent Screen ATS-85 analyzer for the detection of glaucomatous patients. Annals of Ophthalmology, 1991, 23, 18-20.	0.0	0
281	The influence of hemodialysis on intraocular pressure: III. Aqueous humor dynamics and tissue hydration. Annals of Ophthalmology, 1991, 23, 31-4.	0.0	7
282	Quantification and Measurement of Human Lens Opacities Using the Lens Opacity Meter. Ophthalmologica, 1990, 201, 45-48.	1.0	12
283	Influence of Lens Opacities on Visual Field Indices. Ophthalmologica, 1990, 201, 180-186.	1.0	8
284	Effects of ketanserin on intraocular pressure. Cardiovascular Drugs and Therapy, 1990, 4, 97-99.	1.3	8
285	Intraocular Pressure in a Healthy Population: A Survey of 751 Subjects. Optometry and Vision Science, 1990, 67, 204-206.	0.6	15
286	Systemic human diseases as oxidative risk factors in cataractogenesis. II. Chronic renal failure. Experimental Eye Research, 1990, 51, 631-635.	1.2	23
287	Oxidative state of glutathione in red blood cells and plasma of diabetic patients: in vivo and in vitro study. Clinical Physiology and Biochemistry, 1990, 8, 204-10.	0.1	30
288	Red cell reduced glutathione and tobacco smoke-induced optic neuropathy. Metabolic, Pediatric, and Systemic Ophthalmology, 1990, 13, 96-8.	0.0	4

#	Article	IF	CITATIONS
289	Effect of vitamin E on the oxidative state of glutathione in plasma. Clinical Physiology and Biochemistry, 1990, 8, 140-3.	0.1	16
290	Anemia and Chronic Renal Failure: The Possible Role of the Oxidative State of Glutathione. Nephron, 1989, 52, 11-14.	0.9	46
291	Cataracts associated with long-term topical steroids. British Journal of Dermatology, 1989, 120, 472-473.	1.4	26
292	Red cell glutathione as a marker of tobacco smoke-induced optic neuropathy. Experimental Eye Research, 1989, 48, 583-586.	1.2	5
293	In vivo Measurement of Human Lens Aging using the Lens Opacity Meter. Ophthalmologica, 1989, 199, 158-161.	1.0	10
294	Chronobiology and Closed-Angle Glaucoma. Optometry and Vision Science, 1988, 65, 916.	0.6	0
295	Systemic Human Diseases as Oxidative Risk Factors in Cataractogenesis. Ophthalmic Research, 1988, 20, 308-316.	1.0	40
296	Effect of Topical Glucocorticoid Administration on the Protein and Nonprotein Sulfhydryl Groups of the Rabbit Lens. Ophthalmic Research, 1987, 19, 351-356.	1.0	19
297	Oxidative state of glutathione in arterial and venous red blood cells and plasma of rabbit. European Journal of Haematology, 1987, 38, 327-330.	1.1	6
298	Effect of vitamin E on glutathione content in red blood cells, aqueous humor and lens of humans and other species. Experimental Eye Research, 1986, 43, 905-914.	1.2	56
299	Vitamin E and red blood cell glutathione. Metabolism: Clinical and Experimental, 1985, 34, 712-714.	1.5	59
300	HIGH FREQUENCY OF LACTOSE ABSORBERS AMONG ADULTS WITH IDIOPATHIC SENILE AND PRESENILE CATARACT IN A POPULATION WITH A HIGH PREVALENCE OF PRIMARY ADULT LACTOSE MALABSORPTION. Lancet, The, 1984, 323, 355-357.	6.3	47